Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks
A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients With Chronic Obstructive Pulmonary Disease
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Alabama
-
Anniston、Alabama、美国、36207-5710
- Novartis Investigative Site
-
Jasper、Alabama、美国、35501
- Novartis Investigative Site
-
-
Arizona
-
Glendale、Arizona、美国、85306
- Novartis Investigator Site
-
Phoenix、Arizona、美国、85006
- Novartis Investigator Site
-
-
California
-
Fullerton、California、美国、92835
- Novartis Investigator Site
-
Los Angeles、California、美国、90048
- Novartis Investigator Site
-
Los Angeles、California、美国、90095
- Novartis Investigator Site
-
Riverside、California、美国、92506
- Novartis Investigator Site
-
-
Florida
-
Clearwater、Florida、美国、33756
- Novartis Investigative Site
-
Clearwater、Florida、美国、33765
- Novartis Investigative Site
-
Hollywood、Florida、美国、33021
- Novartis Investigative Site
-
Miami、Florida、美国、33145
- Novartis Investigative Site
-
Tampa、Florida、美国、33603
- Novartis Investigative Site
-
Winter Park、Florida、美国、32789
- Novartis Investigative Site
-
-
Georgia
-
Atlanta、Georgia、美国、30342
- Novartis Investigative Site
-
-
Illinois
-
Normal、Illinois、美国、61761
- Novartis Investigator Site
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- Novartis Investigator Site
-
-
Kentucky
-
Madisonville、Kentucky、美国、42431
- Novartis Investigative Site
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70808
- Novartis Investigator Site
-
Opelousas、Louisiana、美国、70570
- Novartis Investigator Site
-
-
Missouri
-
St. Charles、Missouri、美国、63301
- Novartis Investigator Site
-
St. Louis、Missouri、美国、63141
- Novartis Investigator Site
-
-
Nebraska
-
Lincoln、Nebraska、美国、68510
- Novartis Investigator Site
-
Omaha、Nebraska、美国、68114
- Novartis Investigator Site
-
Omaha、Nebraska、美国、68134
- Novartis Investigator Site
-
-
Nevada
-
Henderson、Nevada、美国、89014
- Novartis Investigator Site
-
Las Vegas、Nevada、美国、89119
- Novartis Investigator Site
-
-
New Jersey
-
Cherry Hill、New Jersey、美国、08003
- Novartis Investigative Site
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87108
- Novartis Investigator Site
-
-
North Carolina
-
Charlotte、North Carolina、美国、28207
- Novartis Investigative Site
-
Raleigh、North Carolina、美国、27607
- Novartis Investigative Site
-
Shelby、North Carolina、美国、28152
- Novartis Investigative Site
-
-
Ohio
-
Canton、Ohio、美国、44718
- Novartis Investigative Site
-
Cincinnati、Ohio、美国、45242
- Novartis Investigator Site
-
Columbus、Ohio、美国、43215
- Novartis Investigative Site
-
Columbus、Ohio、美国、43213
- Novartis Investigative Site
-
Marion、Ohio、美国、43302
- Novartis Investigator Site
-
-
Oregon
-
Eugene、Oregon、美国、97404
- Novartis Investigator Site
-
Medford、Oregon、美国、97504
- Novartis Investigator Site
-
-
Rhode Island
-
Cumberland、Rhode Island、美国、02864
- Novartis Investigative Site
-
Pawtucket、Rhode Island、美国、02860
- Novartis Investigative Site
-
-
South Carolina
-
Charleston、South Carolina、美国、29407
- Novartis Investigative Site
-
Charleston、South Carolina、美国、29412
- Novartis Investigative Site
-
Easley、South Carolina、美国、29640
- Novartis Investigative Site
-
Greenville、South Carolina、美国、29615
- Novartis Investigative Site
-
North Charleston、South Carolina、美国、29406
- Novartis Investigative Site
-
Spartanburg、South Carolina、美国、29303
- Novartis Investigative Site
-
Union、South Carolina、美国、29379
- Novartis Investigative Site
-
-
Texas
-
Arlington、Texas、美国、76012
- Novartis Investigator Site
-
Dickinson、Texas、美国、77539
- Novartis Investigator Site
-
El Paso、Texas、美国、79903
- Novartis Investigator Site
-
McKinney、Texas、美国、75069
- Novartis Investigator Site
-
-
Vermont
-
South Burlington、Vermont、美国、05403
- Novartis Investigative Site
-
-
Virginia
-
Richmond、Virginia、美国、23229
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008) and:
- Smoking history of at least 10 pack-years
- Post-bronchodilator FEV1 <80% and ≥30% of the predicted normal value
- Post-bronchodilator FEV1/FVC (forced vital capacity) <70%
Exclusion Criteria:
- Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization for in the 6 weeks prior to screening
- Patients who have had a respiratory tract infection within 6 weeks prior to screening
- Patients with concomitant pulmonary disease
- Patients with a history of asthma
- Patients with diabetes Type I or uncontrolled diabetes Type II
- Any patient with lung cancer or a history of lung cancer
- Patients with a history of certain cardiovascular comorbid conditions
Other protocol-defined inclusion/exclusion criteria may apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Indacaterol 75 µg
Indacaterol 75 µg inhaled once daily in the morning via Concept1, a single dose dry powder inhaler (SDDPI), for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study. |
Once daily via single-dose dry powder inhaler (SDDPI)
|
安慰剂比较:Placebo
Placebo to indacaterol inhaled once daily in the morning via Concept1, a SDDPI, for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study. |
Once daily via SDDPI
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment
大体时间:after 12 weeks
|
Spirometry was conducted according to internationally accepted standards.
Trough FEV1 was defined as the average of the 23 hour 10 minute and 23 hour 45 minute post-dose FEV1 readings.
Mixed model used baseline FEV1, FEV1 prior to and 10-15 minutes post inhalation of albuterol, and FEV1 prior to and 50-70 minutes post inhalation of ipratropium as covariates.
|
after 12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Transition Dyspnoea Index (TDI) Focal Score After 12 Weeks of Treatment
大体时间:after 12 weeks
|
TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort.
Each domain is scored from -3 (major deterioration) to 3 (major improvement) to give an overall TDI focal score of -9 to 9 with a negative score indicating a deterioration from baseline.
A 1 unit difference in the TDI focal score is clinically significant.
Mixed model used baseline dyspnoea index, FEV1 prior to and 10-15 minutes post inhalation of albuterol, and FEV1 prior to and 50-70 minutes post inhalation of ipratropium as covariates.
|
after 12 weeks
|
合作者和调查者
赞助
出版物和有用的链接
一般刊物
- Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B. Efficacy of indacaterol 75 mug once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. COPD. 2012 Dec;9(6):629-36. doi: 10.3109/15412555.2012.729623. Epub 2012 Sep 28.
- Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B. Efficacy and tolerability of indacaterol 75 mug once daily in patients aged >/=40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther. 2011 Dec;33(12):1974-84. doi: 10.1016/j.clinthera.2011.11.009.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.